NYSE: $LLY
Eli Lilly and Company has announced a significant strategic move to bolster its capabilities in advanced therapeutics by entering into a definitive agreement to acquire Orna Therapeutics, Inc. This acquisition focuses on integrating Orna’s innovative platform for engineering immune cells directly within the body, aiming to revolutionize the treatment landscape for various diseases, particularly B cell-driven autoimmune conditions.
The Promise of In Vivo Cell Engineering
Orna Therapeutics is at the forefront of developing a novel therapeutic class that leverages engineered circular RNA (oRNA®) combined with proprietary lipid nanoparticles (LNPs). This technology allows the patient’s own body to generate therapeutic cells in vivo, circumventing the considerable hurdles associated with traditional, complex, and costly ex vivo cell therapy manufacturing processes.
The potential impact of this approach is substantial. Current cell therapies, while groundbreaking, often face logistical and economic challenges that limit broad patient access. Lilly recognizes that Orna’s platform offers a pathway to scalability and efficiency, potentially delivering these potent treatments to a much wider population.
A Leading Pipeline Candidate: ORN-252
Central to this acquisition is Orna’s lead program, ORN-252. This therapy is poised to enter clinical trials as an in vivo Chimeric Antigen Receptor T-cell (CAR-T) therapy specifically targeting CD19. Its primary goal is to treat B cell-driven autoimmune diseases. Early research suggests that Orna’s circular RNA technology might lead to more durable expression of therapeutic proteins compared to existing RNA or cell therapy platforms, potentially offering treatments previously deemed unachievable.
Dr. Francisco Ramírez-Valle, Senior Vice President and Head of Immunology Research and Early Clinical Development at Lilly, emphasized this potential: “Early autologous CAR-T studies have shown the promise of cell therapy for patients with autoimmune diseases, but the complexity, cost, and logistics of ex vivo approaches make it challenging to deliver these breakthroughs to the broader population of patients who need them. We look forward to working with Orna colleagues to potentially create an entirely new class of genetic medicines and cell therapies for patients who today have limited or no treatment options.”
Strategic Rationale for Lilly
This transaction provides Lilly with a broad, foundational platform for long-term innovation in genetic medicine and in vivo cell engineering. By integrating Orna’s capabilities, Lilly significantly advances its pipeline in immunology and establishes a robust technological asset for future therapeutic development across multiple disease areas.
Joe Bolen, Ph.D., Chief Executive Officer of Orna Therapeutics, expressed optimism about the collaboration: “At Orna, we believe our circular RNA technology paired with our best-in-class LNP delivery platform have the potential to create in vivo CAR-T therapies for patients across a wide range of B cell-driven autoimmune diseases. We are excited to join forces with Lilly, an industry leader in the development of patient-centric therapeutics to realize the full potential of these technologies.”
Transaction Details
Under the definitive agreement, Eli Lilly and Company will acquire Orna. The total consideration for Orna shareholders could reach up to $2.4 billion in cash, structured as an upfront payment followed by subsequent payments contingent upon the achievement of specified clinical development milestones.
Lilly’s commitment to scientific advancement, as highlighted by its ongoing work in diabetes, obesity, Alzheimer’s disease, oncology, and immune system disorders, is further solidified by this acquisition. This move positions Lilly to address some of the most significant unmet medical needs using cutting-edge genetic and cellular engineering techniques.
The transaction is subject to customary closing conditions and regulatory approvals.